Maravai LifeSciences Holdings Inc

Maravai LifeSciences (MRVI) sees a sharp rise in options trading as investors eye its drug‑dev focus—despite a negative P/E, the stock’s volatility and market cap suggest growth potential for the health‑care holding firm.

Maravai LifeSciences Holdings Inc has exceeded first-quarter 2025 revenue expectations, but faces financial challenges, including a net loss and goodwill impairment, leaving investors hopeful yet wary of the company’s future prospects.